(Added MXE jpg) |
|||
| Line 1: | Line 1: | ||
| + | [[File:Mxe.jpg|200px|right]] | ||
Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of [[Ketamine]] and [[PCP]]. It was first publicly reported in 2010. Some say it's similar to Ketamine or high doses of DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed specifically for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor (SRI). The N-Ethyl group on this compound increases potency. | Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of [[Ketamine]] and [[PCP]]. It was first publicly reported in 2010. Some say it's similar to Ketamine or high doses of DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed specifically for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDA receptor antagonist and unlike ketamine also acts as Serotonin Reuptake Inhibitor (SRI). The N-Ethyl group on this compound increases potency. | ||
Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or high doses of DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed specifically for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor antagonistA substance that interferes with or inhibits the physiological action of another. and unlike ketamine also acts as SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Reuptake Inhibitor (SRISerotonin Reuptake Inhibitor). The N-Ethyl group on this compound increases potency.
| Threshold | 5-20mg |
| Low | 10-30mg |
| Common | 40-60mg |
| Strong | 50-100mg+ |
| Threshold | 5-15mg |
| Low | 15-30mg |
| Common | 30-50mg |
| Strong | 50-75mg |
| Hole | 75-100mg+ |
| Threshold | 5-10mg |
| Low | 10-20mg |
| Common | 40-60mg |
| Strong | 60-75mg |
| Hole | 75-100mg+ |
| Onset | 30-60 minutes |
| Total | 3-6 hours |
| After-effects | 2-48 hours (dose-dependent) |
| Onset | 5-40 minutes |
| Total | 3-6 hours |
| After-effects | 2-48 hours (dose-dependent) |
| Onset | 15-45 minutes |
| Total | 3-6 hours |
| After-effects | 2-48 hours (dose-dependent) |
Examination of MXEMethoxetamine molecule showed that, similar to Ketamine, the 2 isomers have totally different effects with the (S) having potent NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. activity (when the -OCH3 is deprotected to -OH, it gets stronger) while the (R) isomerEach of two or more compounds with the same formula but a different arrangement of atoms in the molecule and different properties. has SRISerotonin Reuptake Inhibitor effects and possibly a opioid metabolite.
MXEMethoxetamine is generally sold racemic.
Methoxetamine is illegal in the US states Arizona[1], Florida[2], Indiana[3], Louisiana[4], Minnesota[5], North Dakota[6], Ohio[7] and Virginia[8]. It is also banned in Brazil, France, Germany, Japan, Russia and the UK[9].